Biogen (NASDAQ:BIIB) Price Target Raised to $230.00

Biogen (NASDAQ:BIIB) had its target price boosted by Barclays from $200.00 to $230.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have an equal weight rating on the biotechnology company’s stock.

A number of other brokerages have also weighed in on BIIB. Citigroup raised their target price on shares of Biogen from $200.00 to $215.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. HSBC boosted their target price on shares of Biogen from $165.00 to $175.00 and gave the stock a “reduce” rating in a research note on Thursday, September 10th. HC Wainwright increased their price target on Biogen from $237.00 to $251.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Oppenheimer reiterated an “outperform” rating and issued a $300.00 price target on shares of Biogen in a research note on Wednesday, July 29th. Finally, Morgan Stanley raised their price objective on Biogen from $222.00 to $231.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Biogen has an average rating of “Moderate Buy” and a consensus price target of $251.00.

Biogen Stock Up 1.6%

BIIB stock opened at $253.62 on Wednesday. The stock has a market capitalization of $37.49 billion, a P/E ratio of 108.38, a price-to-earnings-growth ratio of 2.92 and a beta of 0.09. The company has a current ratio of 1.95, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. Biogen has a 12 month low of $146.52 and a 12 month high of $258.78. The firm has a 50-day moving average price of $227.08 and a 200-day moving average price of $201.04.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.63. The company had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.63 billion. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the company posted $4.81 EPS. As a group, equities research analysts anticipate that Biogen will post 12.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Biogen

Several hedge funds have recently added to or reduced their stakes in BIIB. Bell Investment Advisors Inc bought a new position in shares of Biogen during the second quarter valued at $27,000. Align Financial LLC lifted its holdings in shares of Biogen by 339.3% during the third quarter. Align Financial LLC now owns 123 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 95 shares during the period. Provenance Wealth Advisors LLC bought a new stake in shares of Biogen in the third quarter worth $29,000. Canton Hathaway LLC bought a new stake in shares of Biogen in the third quarter worth $31,000. Finally, Ashurst Perkins Coie Trust Co grew its stake in shares of Biogen by 92.2% in the third quarter. Ashurst Perkins Coie Trust Co now owns 173 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 83 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
• Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
• Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
• Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
• Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
• Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.